Galectin Therapeutics (GALT) Misses Q3 EPS by 14c

Galectin Therapeutics (NASDAQ: GALT) reported Q3 EPS of ($0.24), $0.14 worse than the analyst estimate of ($0.10).

For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• S&P 500 eyes record as retail slump, Iran risk set up pivotal week
• Allogene (ALLO) Reiterated at Market Outperform by Citizens: 'ALPHA3 Trial is On-Track'